The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
HDAC expression and clinical prognosis in human malignancies
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Anticancer activities of histone deacetylase inhibitors
Bolden, J. E., Peart, M. J., & Johnstone, R. W. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2133 · Cited by 2,919 · cited 2×
“Since HDI have already entered late phase clinical trials and even have been approved for therapy [7–9], it is surprising that this question has not been addressed so far.”
BackgroundHistone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer
Minucci, S., & Pelicci, P. G. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1779 · Cited by 2,200
Acetylation and deacetylation of non-histone proteins
Glozak, M. A., Sengupta, N., Zhang, X., & Seto, E. (2005) · Gene · doi:10.1016/j.gene.2005.09.010 · Cited by 1,584 · cited 1×
“tion factors and enzymes involved in the determination of malignant cell behaviour, which changes their activity, subcellular localisation and interaction partners [5,6].”
BackgroundHistone deacetylase inhibitors: molecular mechanisms of action
Xu, W. S., Parmigiani, R. B., & Marks, P. A. (2007) · Oncogene · doi:10.1038/sj.onc.1210620 · Cited by 1,542 · cited 2×
“A disrupted equilibrium with preponderance of the deacetylase system leads to transcriptional repression of a diverse set of genes mainly involved in the regulation of proliferation, migration, angiogenesis, differentiation, invasion, and metastasis [3,4].”
BackgroundEpigenetic therapy of cancer: past, present and future
Yoo, C. B., & Jones, P. A. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1930 · Cited by 1,289
Marks, P. A., & Breslow, R. (2007) · Nature Biotechnology · doi:10.1038/nbt1272 · Cited by 1,196
Global histone modification patterns predict risk of prostate cancer recurrence
Seligson, D. B., Horvath, S., Shi, T., Yu, H., Tze, S., Grunstein, M., & Kurdistani, S. K. (2005) · Nature · doi:10.1038/nature03672 · Cited by 1,092
Histone deacetylases and cancer
Glozak, M. A., & Seto, E. (2007) · Oncogene · doi:10.1038/sj.onc.1210610 · Cited by 1,031
Wilson, A. J., Byun, D.-S., Popova, N., Murray, L. B., L'Italien, K., Sowa, Y., Arango, D., Velcich, A., Augenlicht, L. H., & Mariadason, J. M. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m510023200 · Cited by 575
Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis
Zhu, P., Martin, E., Mengwasser, J., Schlag, P., Janssen, K.-P., & Göttlicher, M. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00114-x · Cited by 525
Cited by
The world of protein acetylation
Drazic, A., Myklebust, L. M., Ree, R., & Arnesen, T. (2016) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2016.06.007 · Cited by 804
HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications
Khan, O., & La Thangue, N. B. (2012) · Immunology & Cell Biology · doi:10.1038/icb.2011.100 · Cited by 450
“Biomarkers HDAC expression Numerous studies have been performed in which expression of HDACs have been assessed using immunohistochemistry ( Table 3 and reviewed in Weicher”
MethodHistone deacetylases and cancer
Barneda-Zahonero, B., & Parra, M. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.07.003 · Cited by 446
Targeted Cancer Therapy: Giving Histone Deacetylase Inhibitors All They Need To Succeed
Gryder, B. E., Sodji, Q. H., & Oyelere, A. K. (2012) · Future Medicinal Chemistry · doi:10.4155/fmc.12.3 · Cited by 404
Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy
Wagner, J. M., Hackanson, B., Lübbert, M., & Jung, M. (2010) · Clinical Epigenetics · doi:10.1007/s13148-010-0012-4 · Cited by 338
Aghdassi, A., Sendler, M., Guenther, A., Mayerle, J., Behn, C.-O., Heidecke, C.-D., Friess, H., Büchler, M., Evert, M., Lerch, M. M., et al. (2012) · Gut · doi:10.1136/gutjnl-2011-300060 · Cited by 289
Müller, B. M., Jana, L., Kasajima, A., Lehmann, A., Prinzler, J., Budczies, J., Winzer, K.-J., Dietel, M., Weichert, W., & Denkert, C. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-215 · Cited by 256
Self-citationMoreno, D. A., Scrideli, C. A., Cortez, M. A. A., De Paula Queiroz, R., Valera, E. T., Da Silva Silveira, V., Yunes, J. A., Brandalise, S. R., & Tone, L. G. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08301.x · Cited by 208
HDAC2: a critical factor in health and disease
Krämer, O. H. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.09.007 · Cited by 157
PROTAC-mediated degradation of class I histone deacetylase enzymes in corepressor complexes
Smalley, J. P., Adams, G. E., Millard, C. J., Song, Y., Norris, J. K. S., Schwabe, J. W. R., Cowley, S. M., & Hodgkinson, J. T. (2020) · Chemical Communications · doi:10.1039/d0cc01485k · Cited by 121
Seo, J., Min, S. K., Park, H.-R., Kim, D. H., Kwon, M. J., Kim, L. S., & Ju, Y.-S. (2014) · Journal of Breast Cancer · doi:10.4048/jbc.2014.17.4.323 · Cited by 100
Inhibition of histone deacetylases sensitizes glioblastoma cells to lomustine
Staberg, M., Michaelsen, S. R., Rasmussen, R. D., Villingshøj, M., Poulsen, H. S., & Hamerlik, P. (2017) · Cellular Oncology · doi:10.1007/s13402-016-0301-9 · Cited by 62
Inhibition of histone deacetylases in melanoma—a perspective from bench to bedside
Hornig, E., Heppt, M. V., Graf, S. A., Ruzicka, T., & Berking, C. (2016) · Experimental Dermatology · doi:10.1111/exd.13089 · Cited by 50
Loh, A. H. P., Stewart, E., Bradley, C. L., Chen, X., Daryani, V., Stewart, C. F., Calabrese, C., Funk, A., Miller, G., Karlstrom, A., et al. (2019) · Cancer Letters · doi:10.1016/j.canlet.2018.10.033 · Cited by 36
Identification of lysine acetylome in cervical cancer by label-free quantitative proteomics
Zhang, L., Wang, W., Zhang, S., Wang, Y., Guo, W., Liu, Y., Wang, Y., & Zhang, Y. (2020) · Cancer Cell International · doi:10.1186/s12935-020-01266-z · Cited by 15
Metadata
- Authors
- Weichert, W.
- Venue
- Cancer Letters
- Publisher
- Elsevier BV
- Published
- 2009-08
- Volume
- 280
- Issue
- 2
- Pages
- 168-176
- ISSN
- 0304-3835 (ISSN-L)
- OpenAlex
- W2148718757
- Cited by
- 409
- References
- 60
- FWCI
- 6.58
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.